A Phase I Study to Evaluate the Safety of Colchicine for Treatment and Prevention of Radiation-Induced Dermatitis.

Inclusion Criteria: - Eight years or older with HNC diagnosis confirmed histologically o Stage 1-3 HNC pathologically confirmed diagnosis of squamous cell carcinoma of the oropharynx, larynx, hypopharynx, nasopharyngeal, or oral cavity - Plan to receive radiotherapy (>60 Gy), chemo-irradiation or bio-radiation either as primary or as a post-operative treatment to the head and neck region - Eastern Cooperative Oncology Group Performance Status (ECOGPS) performance status 0 or 1 - Comply with the study protocol - Capable of signing a written informed consent Exclusion Criteria: - An allergy, intolerance, or contraindication to colchicine - Current treatment with colchicine for medical conditions, e.g. gout and Familial Mediterranean Fever (FMF) - Estimated glomerular filtration rate (GFR) < 55 ml/min since colchicine should not be given - Severe liver disease or current aminotransferase levels of more than 1.5 times the upper limit of the normal range - Previous irradiation to the head and/or neck region - Distant metastatic disease or locally recurrent disease - Pre-existing skin rashes, ulcerations, or open wounds in the treatment area - Known allergic and other systemic skin diseases even when not directly affecting irradiated fields - Substance abuse, medical conditions, and/or social issues that would limit conduct or follow-up in the research study, in the opinion of the investigator - Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator - Using high doses of non-steroidal anti-inflammatory drugs - Pregnant and lactating women - Psychiatric illness that would prevent the patient from giving informed consent - Taking cetuximab or other radiosensitizing agents.